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Abstract 
The Na/K‐ATPase has a signaling function which appears to be separate from its ion 
pumping function. This signaling function refers to the transduction of conformational 
changes in the Na/K‐ATPase 1 subunit. These changes activate Src’s tyrosine kinase 
activity, triggering a cascade which generates reactive oxygen species (ROS), modulates 
other signaling pathways, and causes many physiological and pathophysiological effects. We 
have recently observed that ROS themselves as well as cardiotonic steroids can actually 
initiate the signal by directly inducing conformational changes in 1. It therefore appears that 
the Na/K‐ATPase signal cascade can serve as a feed forward amplification for ROS with 
circulating cardiotonic steroids setting the gain.  Work in both cellular and animal models of 
disease suggest that this amplification process is activated in conditions characterized by 
oxidant stress ranging from cancer to obesity/metabolic syndrome and may serve as a 
potential clinical target for interventions. 
Keywords:   
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The sodium potassium adenosine triphosphatase (Na/K‐ATPase) was discovered by Jens 
Skou in the 1950s and found to be the predominant ion pump in animal tissues.1 The Na/K‐ 
ATPase consists of at least 2 peptides named  and  which each possess different isoforms. 
The 1 isoform appears to be displayed ubiquitously in different animal tissues, and for many 
years was considered to be less important in terms of cell signaling than other  isoforms 
(e.g., 2 and 3) which are expressed more selectively.2  Although considerable attention has 
been devoted to the study of the Na/K‐ATPase and its isoforms, the discovery that 
conformational changes in 1 can induce a signal cascade initiated within caveolae and/or 
lipid rafts has only occurred within the last 20 years.1  Our group has demonstrated that the 
Na/K‐ATPase 1 subunit regulates the activity of membrane associated Src, and that 
conformational changes in 1 may disinhibit Src’s tyrosine kinase, leading to activation of a 
signal cascade which generates reactive oxygen species (ROS), activates mitogen activated 
protein kinase (MAPK), mammalian target of rapamycin (mTOR) as well as many other 
cellular processes.3-6  The contribution of other α isoforms to signaling is less clear at present.  
More recently, we have observed that in addition to generating ROS, the signal cascade can 
be initiated by H2O2, creating a feed forward amplification of oxidant stress.7  Specifically, it 
appears that either cardiotonic steroids or oxidant stress directly can cause the reversible 
carbonylation of the 1 subunit at specific sites.7  As this process can also be initiated by the 
binding of cardiotonic steroids to the Na/K‐ATPase 1 subunit, we would argue that these 
cardiotonic steroids set the gain for the amplification of ROS.  Specifically, increases in the 
concentration of cardiotonic steroids might allow for greater amplification of ROS generated 
by other cellular process related to signaling and/or energy metabolism.  A schematic of this 
process is shown in Figure 1.   
 
 
 
10
Xie, PhD and Shapiro, MD: Amplification of oxidant stress
Published by Marshall University's Joan C. Edwards School of Medicine, 2016
 Figure 1:  Schematic showing Na/K‐ATPase as reactive oxygen species (ROS) amplifier 
system. CTS‐cardiotonic steroids, Orange dimer is Na/K‐ATPase. pNaKtide refers 
to peptide formed from epitope of Na/K‐ATPase 1 subunit known to bind Src 
tyrosine kinase fused with TAT leader sequence. 
Using this framework, we have identified that activation of this oxidant amplification occurs 
in settings ranging from cancer growth to organ fibrosis.8-13  We find that we can interfere 
with this process by downregulation of the expression of the Na/K‐ATPase, elimination of 
caveolar structure, antibodies to cardiotonic steroids, pharmacological antagonists of 
cardiotonic steroid binding to the Na/K‐ATPase, Src inhibitors and perhaps most directly, by 
a peptide developed from the 1 Na/K‐ATPase subunit merged with a TAT leader sequence 
to allow for cellular uptake and membrane distribution called pNaKtide.3, 13-17  We propose 
that virtually any of these strategies might have potential clinical application in conditions 
associated with oxidant stress.     
Testing our hypothesis is non‐trivial. First, it is likely if not certain that normal physiological 
functions are regulated in part by this oxidant amplification. Specifically, we know that 
urinary sodium excretion is impacted by this pathway in rodents, and we have reason to 
believe that fetal growth and organ development may also require the participation of this 
pathway.18   Any clinical testing would need to anticipate these potential toxicities. Second, 
existing pharmacological agents which antagonize the cardiotonic steroid regulation of this 
amplifier system may be promiscuous. Spironolactone and its major metabolite, canrenone, 
while satisfying pharmacological evidence for being competitive antagonists of cardiotonic 
steroid binding to the Na/K‐ATPase, are also well known to have effects on the 
mineralocorticoid receptor.12  Lastly, most agents which target this system including 
humanized antibodies to cardiotonic steroids or peptides like pNaKtide have yet to be 
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subjected to rigorous toxicological analysis.  Clearly, testing of these agents in actual clinical 
scenarios will need additional preclinical work to ensure safe study.  
That said, we believe there is widespread potential application. Accumulation of oxidant 
injury appears to be central to the pathogenesis of many clinical problems, some of which 
have been effectively recalcitrant to current therapies. It is our contention that addressing the 
cellular amplification of oxidant stress may allow for novel therapies that might effectively 
treat some of these clinical problems.  
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